Predicine
Predicine develops a next-generation liquid biopsy platform for precision cancer therapies, using its proprietary GeneRADAR technology to simultaneously profile cell-free DNA and RNA from a single tube of blood. The platform offers molecular profiling assays including PredicineATLAS for 600 genes, PredicineCARE for 200 genes, PredicineRNA for fusions and splicing, PredicineBEACON for MRD detection, and…
Funding snapshot
About
Predicine develops a next-generation liquid biopsy platform for precision cancer therapies, using its proprietary GeneRADAR technology to simultaneously profile cell-free DNA and RNA from a single tube of blood. The platform offers molecular profiling assays including PredicineATLAS for 600 genes, PredicineCARE for 200 genes, PredicineRNA for fusions and splicing, PredicineBEACON for MRD detection, and PredicineHEME. Predicine also introduces urine-based liquid biopsy for painless cancer detection, with more robust variant detection in genitourinary cancers. Founded in 2015 and headquartered in Hayward, California, the company has raised approximately $41.3M in Series B funding. Predicine differentiates itself through dual DNA and RNA analysis, low input requirements from as little as 0.4mL of plasma, CLIA and CAP certified facilities in California and Shanghai, and partnerships supporting biomarker-driven clinical trials for leading biopharmaceutical companies.
Business model
Oncology > In-Vitro Diagnostic Tests > Pan Cancer,
Genomics > Applied Genomics > Clinical Genomics > Diagnostics > Sequencing-based > Liquid Biopsy > DNA and RNA
Institutional investors
Latest coverage
No articles yet.
Similar startups
Immuneel
Developer of T-cell therapies for the treatment of cancer. It is developing cell therapies by using genetic engineering that modifies healthy immune cells to target cancerous cells.
ImmunoACT
Developer of cell and gene therapies for cancer treatment. It offers a lead product NexCAR19 Talicabtagene autoleucel for B‑cell malignancies such as B‑lymphoma and B‑acute lymphoblastic leukaemia.
HaystackAnalytics
EmbeDL is a provider of an edge AI optimization and deployment platform that streamlines the path from deep learning model development to hardware-ready deployment on embedded systems.
4baseCare
Sitehop is a provider of hardware-enforced network encryption solutions that delivers ultra-low latency, quantum-ready encryption for data-in-motion in critical networks through its SAFE Series product line.